BST:N18

Stock Analysis Report

Executive Summary

Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • Nemaura Medical has significant price volatility in the past 3 months.
  • Nemaura Medical is covered by less than 3 analysts.

Share Price & News

How has Nemaura Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-25.1%

BST:N18

-1.3%

DE Medical Equipment

-1.5%

DE Market


1 Year Return

n/a

BST:N18

4.1%

DE Medical Equipment

-10.4%

DE Market

No trading data on N18.

No trading data on N18.


Share holder returns

N18IndustryMarket
7 Day-25.1%-1.3%-1.5%
30 Day-11.6%-2.3%-4.6%
90 Day-12.0%-0.2%-4.6%
1 Yearn/a5.7%4.1%-7.6%-10.4%
3 Yearn/a111.3%105.7%9.4%0.03%
5 Yearn/a265.3%247.3%25.6%8.1%

Price Volatility Vs. Market

How volatile is Nemaura Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Nemaura Medical undervalued based on future cash flows and its price relative to the stock market?

127.19x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Nemaura Medical to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Nemaura Medical to establish if it is available at substantial discount.


Price Based on Earnings

Nemaura Medical is loss making, we can't compare its value to the DE Medical Equipment industry average.

Nemaura Medical is loss making, we can't compare the value of its earnings to the Germany market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Nemaura Medical, we can't assess if its growth is good value.


Price Based on Value of Assets

Nemaura Medical is overvalued based on assets compared to the DE Medical Equipment industry average.


Next Steps

Future Growth

How is Nemaura Medical expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

12.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nemaura Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Nemaura Medical performed over the past 5 years?

-28.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Nemaura Medical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Nemaura Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Nemaura Medical's 1-year growth to the DE Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Nemaura Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Nemaura Medical has efficiently used its assets last year compared to the DE Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Nemaura Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Nemaura Medical's financial position?


Financial Position Analysis

Nemaura Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Nemaura Medical's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Nemaura Medical has no debt.

Nemaura Medical has not taken on any debt in the past 5 years.


Balance Sheet

Low level of unsold assets.

Nemaura Medical has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Nemaura Medical has less than a year of cash runway based on current free cash flow.

Nemaura Medical has less than a year of cash runway if free cash flow continues to grow at historical rates of 42.6% each year.


Next Steps

Dividend

What is Nemaura Medical's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Nemaura Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Nemaura Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Nemaura Medical has not reported any payouts.

Unable to verify if Nemaura Medical's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Nemaura Medical has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Nemaura Medical's salary, the management and board of directors tenure and is there insider trading?

2.1yrs

Average board tenure


CEO

Faz Chowdhury (46yo)

10.6yrs

Tenure

US$105,258

Compensation

Dr. Dewan Fazlul Hoque Chowdhury, also known as Faz, founded Nemaura Pharma Limited and also serves as its serves as its Chief Executive Officer. Dr. Chowdhury has been the Chairman, President and Chief Ex ...


CEO Compensation Analysis

Faz's remuneration is lower than average for companies of similar size in Germany.

Faz's compensation has been consistent with company performance over the past year, both up more than 20%.


Board Age and Tenure

2.1yrs

Average Tenure

46yo

Average Age

The average tenure for the Nemaura Medical board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Bashir Timol (45yo)

    Chief Business Officer & Director

    • Tenure: 5.7yrs
  • Richard Toon (48yo)

    Technical & Business Development Manager

    • Tenure: 0.0yrs
  • Faz Chowdhury (46yo)

    Chairman

    • Tenure: 10.6yrs
    • Compensation: US$105.26k

Board Members

  • Bashir Timol (45yo)

    Chief Business Officer & Director

    • Tenure: 5.7yrs
  • Faz Chowdhury (46yo)

    Chairman

    • Tenure: 10.6yrs
    • Compensation: US$105.26k
  • Tim Johnson (35yo)

    Independent Director

    • Tenure: 2.1yrs
    • Compensation: US$6.51k
  • Salim Natha (52yo)

    Independent Director

    • Tenure: 2.1yrs
    • Compensation: US$6.51k
  • Thomas Moore (55yo)

    Independent Director

    • Tenure: 2.0yrs
    • Compensation: US$6.51k

Company Information

Nemaura Medical Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Nemaura Medical Inc.
  • Ticker: N18
  • Exchange: BST
  • Founded: 2009
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$166.393m
  • Listing Market Cap: US$149.953m
  • Shares outstanding: 208.02m
  • Website: https://nemauramedical.com

Number of Employees


Location

  • Nemaura Medical Inc.
  • Advanced Technology Innovation Centre
  • Loughborough University Science and Enterprise Parks
  • Loughborough
  • Leicestershire
  • LE11 3QF
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NMRDNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDDec 2014
N18BST (Boerse-Stuttgart)YesCommon SharesDEEURDec 2014

Biography

Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/18 22:56
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.